Fabris, M <br/><br/>
The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis.  [electronic resource] 

 -  The pharmacogenomics journal  06 2016 
 - 238-42 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1473-1150 
<br/><br/><label>Standard No.: </label>10.1038/tpj.2015.49  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antirheumatic Agents--adverse effects<br/>Biological Products--adverse effects<br/>Chi-Square Distribution<br/>Drug Substitution<br/>Female<br/>Genetic Association Studies<br/>Homozygote<br/>Humans<br/>Interleukin-6--genetics<br/>Italy<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Odds Ratio<br/>Pharmacogenomic Testing<br/>Pharmacogenomic Variants--genetics<br/>Phenotype<br/>Polymorphism, Single Nucleotide<br/>Predictive Value of Tests<br/>Promoter Regions, Genetic<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Sex Factors<br/>Spondylarthritis--blood<br/>Time Factors<br/>Treatment Failure<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>Young Adult